Galilei Biosciences

Drug development company targeting PARP1, a central regulator of DNA damage repair, glucose and lipid metabolism, to develop therapies for metabolic health and human longevity.

Location
Boston, Massachusetts, USA
Founded
2021
Investors
1
Categories
biotech, longevity, metabolic-health, cardiovascular, drug-discovery

Investors

NameLocationTypeStagesPortfolio
Apollo Health VenturesDusseldorf, Germany / Boston, USAbiotech-focused
seedseries-a+1
15